Hope for Cirrhosis Patients with Genotype 1 Hepatitis C Virus Who Failed the Previous Treatment

Jung Hyun Kwon

doi:10.4166/kjg.2015.66.2.131

Journal List > Korean J Gastroenterol > v.66(2) > 1007411

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kwon: Hope for Cirrhosis Patients with Genotype 1 Hepatitis C Virus Who Failed the Previous Treatment

Research Update

Korean J Gastroenterol 2015;66(2):131-133.

Published online: 4 October 2015

DOI: https://doi.org/10.4166/kjg.2015.66.2.131

Hope for Cirrhosis Patients with Genotype 1 Hepatitis C Virus Who Failed the Previous Treatment

Jung Hyun Kwon

Department of Internal Medicine, The Catholic University of Korea, Incheon St. Mary's Hospital, Incheon, Korea

Correspondence to: Jung Hyun Kwon, Department of Internal Medince, The Catholic University of Korea Incheon St. Mary's Hospital, 56 Dongsu-ro, Bupyeong-gu, Incheon 21431, Korea. Tel: +82-32-280-5886, Fax: +82-32-280-5987, E-mail: doctorkwon@catholic.ac.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Article

Ledipasvir-sofosbuvir with or without Ribavirin to Treat Patients with HCV Genotype 1 Infection and Cirrhosis Non-responsive to Previous Protease-inhibitor Therapy: A Randomised, Double-blind, Phase 2 Trial (SIRIUS)

References

1. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatmentnaïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013; 58:1918–1929.

2. Colombo M, Strasser S, Moreno C, et al. Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program. J Hepatol. 2014; 61:976–983.

3. Hézode C, Fontaine H, Dorival C, et al. CUPIC Study Group. Effectiveness of telaprevir or boceprevir in treatmentexperienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014; 147:132–142. e4.

4. Vierling JM, Zeuzem S, Poordad F, et al. Safety and efficacy of bo-ceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: metaanalysis of 5 trials. J Hepatol. 2014; 61:200–209.

5. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014; 383:515–523.

6. Bourlière M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous pro-tease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015; 15:397–404.

7. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2014; 20:89–136.

8. Poordad F, McCone J Jr, Bacon BR, et al. SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364:1195–1206.

9. Jacobson IM, McHutchison JG, Dusheiko G, et al. ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364:2405–2416.

10. Sherman KE, Flamm SL, Afdhal NH, et al. ILLUMINATE Study Team. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011; 365:1014–1024.

11. Bacon BR, Gordon SC, Lawitz E, et al. HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364:1207–1217.

12. Zeuzem S, Andreone P, Pol S, et al. REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364:2417–2428.

13. Park SH, Park CK, Lee JW, et al. Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multicenter, retrospective observational study. Gut Liver. 2012; 6:98–106.

14. Kwon JH, Bae SH, Choi JY, et al. Assessment of the efficacy of reducing peginterferon alpha-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C. Korean J Intern Med. 2009; 24:203–211.

15. Sinn DH, Kim YJ, Lee ST, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients. J Gastroenterol Hepatol. 2011; 26:1374–1379.

16. Park SY, Rim MY, Yo IK, et al. Efficacy of peginterferon and ribavirin combination therapy of chronic hepatitis C: a pooled analysis. Korean J Gastroenterol. 2012; 60:306–314.

17. Kwon JH, Bae SH, Lee YJ, et al. The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (≥80 % full dose) of peginterferon alfa-2a: a prospective randomized multicenter trial. Hepatol Int. 2013; 7:1000–1009.

18. Jung YK, Kim JH, Ahn SM, et al. Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans. J Clin Gastroenterol. 2013; 47:644–650.

19. Afdhal N, Reddy KR, Nelson DR, et al. ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014; 370:1483–1493.

20. AASLD/IDSA HCV Guidance Panel. Hepatitis C Guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with Hepatitis C virus. Hepatology. 2015. DOI: doi:10.1002/hep.27950. [Epub ahead of print].

TOOLS

Similar articles